Log In
BCIQ
Print this Print this
 

Biosimilar rituximab (AP056)

  Manage Alerts
Collapse Summary General Information
Company Aprogen Inc.
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationLymphoma
Indication DetailsTreat lymphoma
Regulatory Designation
PartnerNichi-Iko Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today